Drug pricing — what you need to know
A tweet from Hillary Clinton and an unapologetically high price tag from Gilead for its hepatitis C cure Sovaldi were all that were needed to bring the drug pricing debate into the mainstream. While this debate was once reserved for out-of-control prices for oncology drugs and the like, it is now a daily reminder that the U.S. healthcare system is a little bit broken.
As Congress continues to argue about whether to repeal and replace Obamacare, the drug pricing landscape is already shifting. Companies are taking an active role in the dialogue and making pledges to limit price increases. Meanwhile, state and federal lawmakers are trying to push for further transparency around drug pricing by using their legislative powers.
In this latest special issue of BioPharma Dive, the team shines a Spotlight on how the drug pricing issue has evolved, what goes into setting a drug price and moves that are being taken to find a solution.
When pricing medications, drugmakers now weigh consumer outrage, negotiating power and calls for transparency. Read More >>
A bruising healthcare fight has sapped Congressional momentum to tackle rising pharmaceutical prices. But efforts at the state-level could pose a challenge to a drug industry still struggling to find its footing in post-Shkreli world. Read More >>
Finding the right ingredients to set the perfect drug price is a little bit of art and a whole lot of science. Read More >>
Such a system rattles patients, but may be a model the industry can get behind. Read More >>
Despite small patient populations and historically high prices, the pricing model for rare disease drugs has reached a turning point, prompting companies and insurers to push for new innovative models. Read More >>
Follow Lisa LaMotta on Twitter